Abbott: Coronary Restenosis trials

The registry lists 29 Coronary Restenosis studies with Abbott as lead sponsor. 1 are open to participants now and 16 have results posted.

Phase 2 2Phase 3 5Phase 4 7No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Abbott Vascular Medical Device RegistryRecruitingNCT04573660
• XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm StudyCompletedNCT01894152Results posted
• ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.CompletedNCT01759290Results posted
• XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm StudyCompletedNCT01249027Results posted
• EXCEL Clinical TrialCompletedNCT01205776Not applicableResults posted
• XIENCE V: SPIRIT WOMEN Sub-studyCompletedNCT01182428Phase 4Results posted
• XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)CompletedNCT01178268Phase 4Results posted
• SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)CompletedNCT01171820Phase 4Results posted
• XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)CompletedNCT01120379Results posted
• A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese PopulationCompletedNCT01115933Not applicableResults posted
• XIENCE V® USA Dual Antiplatelet Therapy (DAPT) CohortCompletedNCT01106534Phase 4Results posted
• XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for JapanCompletedNCT01086228Results posted
• ABSORB EXTEND Clinical InvestigationCompletedNCT01023789Not applicableResults posted
• SPIRIT PRIME Clinical TrialCompletedNCT00916370Phase 3Results posted
• ABSORB Clinical Investigation, Cohort BCompletedNCT00856856Not applicableResults posted
• EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel DiseaseCompletedNCT00531011Phase 4Results posted
• SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)CompletedNCT00180479Phase 3Results posted
• To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated VesselsCompletedNCT01977534
• EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel DiseaseCompletedNCT01310309
• EXCEL Clinical Trial (Universal Registry)CompletedNCT01205789
• Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up PeriodCompletedNCT00882219Phase 3
• XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm StudyCompletedNCT00631228
• XIENCE V: SPIRIT WOMENCompletedNCT00496938Phase 4
• SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in EuropeCompletedNCT00402272Phase 4
• ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical InvestigationCompletedNCT00300131
• PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic LesionsCompletedNCT00180466
• SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent SystemCompletedNCT00180310Phase 3
• Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesCompletedNCT00148356Phase 2/3
• Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesCompletedNCT00140101Phase 2